MSc. G.A. (Göktuğ) Aba

I studied Life Science and Technology at TU Delft and Leiden University and obtained my masters in Life Science and Technology at Leiden University where I did my internship in the group of Sander van Kasteren. I combined the cytotoxic activity of cytokines with targeting properties of nanobodies to develop a new immunocytokine with reduced side effects, potentially to be used as anti-cancer drug. I started his PhD in 2021 in the CCB group at the LUMC supervised by Thom Sharp and Ferenc Scheeren.

I am working as a PhD student at the LUMC and combining the DNA nanotechnology with immunology to develop new agonistic antibody-based immunotherapeutics. My interests lie in the activation of co-stimulatory T-cell receptors with agonistic nanobodies to bypass T-cell exhaustion and induce activation.